Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age

Li Min Huang, Chin Yun Lee, Tzou Yien Lin, Jong Min Chen, Ping Ing Lee, Ching Ying Hsu

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A second generation acellular pertussis vaccine (component pertussis vaccine) containing purified pertussis toxin (PT) and filamentous haemagglutinin (FHA) was tested for its immunogenicity and safety in 2-month-old infants in comparison with first-generation acellular and whole-cell pertussis vaccines. At the ages of 2, 4, 6, and 18 months, respectively, 350 subjects were inoculated one dose of pertussis vaccine, which was combined with diphtheria and tetanus toxoids. Both acellular and component vaccines elicited significantly much fewer local and systemic reactions than whole-cell vaccine did. Besides, although not reaching statistical significance, the component vaccine was less reactogenic than the acellular vaccine. After each dose of the primary immunization, antibodies against PT and FHA were much higher in acellular and component pertussis vaccinees than in whole-cell vaccinees. However, at 18 months of age, just before the booster dose, both anti-PT and anti-FHA declined very close to, or even lower than, the prevaccination levels in all three groups and then responded rapidly to a booster dose to attain high levels. The booster responses were also significantly higher (P < 0.01)) in acellular and component groups than in whole-cell group. Component and acellular vaccines induced similar levels of anti-FHA but the former induced higher anti-PT than the latter (P < 0.01). Our results indicate that both in primary immunization and as a booster, acellular and component pertussis vaccines are much more immunogenic for PT and FHA and much less reactogenic than whole-cell vaccine. However, the persistence of anti-PT and anti-FHA was not as good as one can expect from other protein antigens without giving a booster dose. A long-term follow-up of the vaccinees has been underway to understand the persistence of these antibodies after the first booster.

Original languageEnglish
Pages (from-to)916-922
Number of pages7
JournalVaccine
Volume14
Issue number9
DOIs
Publication statusPublished - Jun 1996
Externally publishedYes

Fingerprint

Pertussis Vaccine
whooping cough
Pertussis Toxin
Hemagglutinins
Cellular Structures
Acellular Vaccines
pertussis toxin
vaccines
hemagglutinins
dosage
Vaccines
cells
Immunization
Diphtheria Toxoid
Tetanus Toxoid
Antibodies
Whooping Cough
immunization
antibodies
Safety

Keywords

  • Acellular pertussis vaccine
  • Antibody persistence
  • Component pertussis vaccine
  • Whole-cell pertussis vaccine

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age. / Huang, Li Min; Lee, Chin Yun; Lin, Tzou Yien; Chen, Jong Min; Lee, Ping Ing; Hsu, Ching Ying.

In: Vaccine, Vol. 14, No. 9, 06.1996, p. 916-922.

Research output: Contribution to journalArticle

Huang, Li Min ; Lee, Chin Yun ; Lin, Tzou Yien ; Chen, Jong Min ; Lee, Ping Ing ; Hsu, Ching Ying. / Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age. In: Vaccine. 1996 ; Vol. 14, No. 9. pp. 916-922.
@article{223f63af89e742ad9346dcf91212d092,
title = "Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age",
abstract = "A second generation acellular pertussis vaccine (component pertussis vaccine) containing purified pertussis toxin (PT) and filamentous haemagglutinin (FHA) was tested for its immunogenicity and safety in 2-month-old infants in comparison with first-generation acellular and whole-cell pertussis vaccines. At the ages of 2, 4, 6, and 18 months, respectively, 350 subjects were inoculated one dose of pertussis vaccine, which was combined with diphtheria and tetanus toxoids. Both acellular and component vaccines elicited significantly much fewer local and systemic reactions than whole-cell vaccine did. Besides, although not reaching statistical significance, the component vaccine was less reactogenic than the acellular vaccine. After each dose of the primary immunization, antibodies against PT and FHA were much higher in acellular and component pertussis vaccinees than in whole-cell vaccinees. However, at 18 months of age, just before the booster dose, both anti-PT and anti-FHA declined very close to, or even lower than, the prevaccination levels in all three groups and then responded rapidly to a booster dose to attain high levels. The booster responses were also significantly higher (P < 0.01)) in acellular and component groups than in whole-cell group. Component and acellular vaccines induced similar levels of anti-FHA but the former induced higher anti-PT than the latter (P < 0.01). Our results indicate that both in primary immunization and as a booster, acellular and component pertussis vaccines are much more immunogenic for PT and FHA and much less reactogenic than whole-cell vaccine. However, the persistence of anti-PT and anti-FHA was not as good as one can expect from other protein antigens without giving a booster dose. A long-term follow-up of the vaccinees has been underway to understand the persistence of these antibodies after the first booster.",
keywords = "Acellular pertussis vaccine, Antibody persistence, Component pertussis vaccine, Whole-cell pertussis vaccine",
author = "Huang, {Li Min} and Lee, {Chin Yun} and Lin, {Tzou Yien} and Chen, {Jong Min} and Lee, {Ping Ing} and Hsu, {Ching Ying}",
year = "1996",
month = "6",
doi = "10.1016/0264-410X(95)00257-2",
language = "English",
volume = "14",
pages = "916--922",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "9",

}

TY - JOUR

T1 - Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age

AU - Huang, Li Min

AU - Lee, Chin Yun

AU - Lin, Tzou Yien

AU - Chen, Jong Min

AU - Lee, Ping Ing

AU - Hsu, Ching Ying

PY - 1996/6

Y1 - 1996/6

N2 - A second generation acellular pertussis vaccine (component pertussis vaccine) containing purified pertussis toxin (PT) and filamentous haemagglutinin (FHA) was tested for its immunogenicity and safety in 2-month-old infants in comparison with first-generation acellular and whole-cell pertussis vaccines. At the ages of 2, 4, 6, and 18 months, respectively, 350 subjects were inoculated one dose of pertussis vaccine, which was combined with diphtheria and tetanus toxoids. Both acellular and component vaccines elicited significantly much fewer local and systemic reactions than whole-cell vaccine did. Besides, although not reaching statistical significance, the component vaccine was less reactogenic than the acellular vaccine. After each dose of the primary immunization, antibodies against PT and FHA were much higher in acellular and component pertussis vaccinees than in whole-cell vaccinees. However, at 18 months of age, just before the booster dose, both anti-PT and anti-FHA declined very close to, or even lower than, the prevaccination levels in all three groups and then responded rapidly to a booster dose to attain high levels. The booster responses were also significantly higher (P < 0.01)) in acellular and component groups than in whole-cell group. Component and acellular vaccines induced similar levels of anti-FHA but the former induced higher anti-PT than the latter (P < 0.01). Our results indicate that both in primary immunization and as a booster, acellular and component pertussis vaccines are much more immunogenic for PT and FHA and much less reactogenic than whole-cell vaccine. However, the persistence of anti-PT and anti-FHA was not as good as one can expect from other protein antigens without giving a booster dose. A long-term follow-up of the vaccinees has been underway to understand the persistence of these antibodies after the first booster.

AB - A second generation acellular pertussis vaccine (component pertussis vaccine) containing purified pertussis toxin (PT) and filamentous haemagglutinin (FHA) was tested for its immunogenicity and safety in 2-month-old infants in comparison with first-generation acellular and whole-cell pertussis vaccines. At the ages of 2, 4, 6, and 18 months, respectively, 350 subjects were inoculated one dose of pertussis vaccine, which was combined with diphtheria and tetanus toxoids. Both acellular and component vaccines elicited significantly much fewer local and systemic reactions than whole-cell vaccine did. Besides, although not reaching statistical significance, the component vaccine was less reactogenic than the acellular vaccine. After each dose of the primary immunization, antibodies against PT and FHA were much higher in acellular and component pertussis vaccinees than in whole-cell vaccinees. However, at 18 months of age, just before the booster dose, both anti-PT and anti-FHA declined very close to, or even lower than, the prevaccination levels in all three groups and then responded rapidly to a booster dose to attain high levels. The booster responses were also significantly higher (P < 0.01)) in acellular and component groups than in whole-cell group. Component and acellular vaccines induced similar levels of anti-FHA but the former induced higher anti-PT than the latter (P < 0.01). Our results indicate that both in primary immunization and as a booster, acellular and component pertussis vaccines are much more immunogenic for PT and FHA and much less reactogenic than whole-cell vaccine. However, the persistence of anti-PT and anti-FHA was not as good as one can expect from other protein antigens without giving a booster dose. A long-term follow-up of the vaccinees has been underway to understand the persistence of these antibodies after the first booster.

KW - Acellular pertussis vaccine

KW - Antibody persistence

KW - Component pertussis vaccine

KW - Whole-cell pertussis vaccine

UR - http://www.scopus.com/inward/record.url?scp=0030174874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030174874&partnerID=8YFLogxK

U2 - 10.1016/0264-410X(95)00257-2

DO - 10.1016/0264-410X(95)00257-2

M3 - Article

C2 - 8843635

AN - SCOPUS:0030174874

VL - 14

SP - 916

EP - 922

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 9

ER -